专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明专利

AU2009330355B2 Triple reuptake inhibitors and methods of their use 未知
公开(公告)号：AU2009330355B2
公开(公告)日：2016-06-30
申请号：AU2009330355
申请日：2009-12-15
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , WANG FENGJIANG , MALCOLM SCOTT C , HEWITT MICHAEL C
IPC分类号： C07D209/08 , A61K31/403 , A61P25/00 , C07D209/52
摘要： Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations containing the compounds are also provided.

32. 发明专利

AU2016200448A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF 未知
公开(公告)号：AU2016200448A1
公开(公告)日：2016-02-18
申请号：AU2016200448
申请日：2016-01-27
申请人： PGI DRUG DISCOVERY LLC , SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , CAMPBELL JOHN EMERSON , HEWITT MICHAEL CHARLES , CAMPBELL UNA , HANANIA TALEEN G
IPC分类号： C07D333/56 , A61K31/381 , A61P25/00 , A61P25/18 , C07D495/04 , C07D495/20
摘要： Provided herein are multicyclic compounds, methods or their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

33. 发明专利

HK1163451A1 PYRROLIDINE TRIPLE REUPTAKE INHIBITORS 未知
公开(公告)号：HK1163451A1
公开(公告)日：2012-09-14
申请号：HK12104305
申请日：2012-05-02
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , MA JIANGUO
IPC分类号： C07D20060101 , A61K20060101 , A61P20060101

34. 发明专利

CA2749309A1 PYRROLIDINE TRIPLE REUPTAKE INHIBITORS 未知
公开(公告)号：CA2749309A1
公开(公告)日：2010-08-12
申请号：CA2749309
申请日：2010-02-05
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , MA JIANGUO
IPC分类号： A01N43/36 , A61K31/40
摘要： In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.

35. 发明公开

EP2812324A4 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF 有权
标题翻译： VERFAHREN ZUR VERWENDUNG DAVON的HEZEROARYLVERBINDUNGEN
公开(公告)号：EP2812324A4
公开(公告)日：2016-01-13
申请号：EP13747266
申请日：2013-02-08
申请人： SUNOVION PHARMACEUTICALS INC , CAMPBELL JOHN EMMERSON , CAMPBELL UNA , HANANIA TALEEN G , SHAO LIMING
发明人： CAMPBELL JOHN EMMERSON , CAMPBELL UNA , HANANIA TALEEN G , SHAO LIMING
IPC分类号： C07D405/04 , C07D409/04 , C07D409/14 , C07D491/048 , C07D495/04
CPC分类号： C07D409/04 , C07D405/04 , C07D409/14 , C07D491/048 , C07D495/04
摘要： Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
摘要翻译：本文提供噻吩化合物，其合成方法，包含该化合物的药物组合物及其用途。本文提供的化合物可用于治疗，预防和/或治疗各种神经障碍，包括但不限于精神病和精神分裂症。

36. 发明公开

EP2393357A4 PYRROLIDINE TRIPLE REUPTAKE INHIBITORS 失效
标题翻译：吡咯烷三重再摄取抑制剂
公开(公告)号：EP2393357A4
公开(公告)日：2013-11-27
申请号：EP10739175
申请日：2010-02-05
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , MA JIANGUO
IPC分类号： A61K31/40 , A61P25/24
CPC分类号： C07D207/06 , A61K31/40 , C07D207/08 , C07D207/12 , C07D405/04

37. 发明专利

AU2016200448B2 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF 未知
公开(公告)号：AU2016200448B2
公开(公告)日：2017-11-09
申请号：AU2016200448
申请日：2016-01-27
申请人： PGI DRUG DISCOVERY LLC , SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , CAMPBELL JOHN EMERSON , HEWITT MICHAEL CHARLES , CAMPBELL UNA , HANANIA TALEEN G
IPC分类号： C07D333/56 , A61K31/381 , A61P25/00 , A61P25/18 , C07D495/04 , C07D495/20
摘要： Provided herein are multicyclic compounds, methods or their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.

38. 发明专利

DK2507245T3 MULTICYKLISKE FORBINDELSER OG FREMGANGSMÅDER TIL ANVENDELSE HERAF 未知
公开(公告)号：DK2507245T3
公开(公告)日：2017-05-22
申请号：DK10835185
申请日：2010-12-03
申请人： SUNOVION PHARMACEUTICALS INC , PGI DRUG DISCOVERY LLC
发明人： SHAO LIMING , CAMPBELL JOHN EMERSON , HEWITT MICHAEL CHARLES , CAMPBELL UNA , HANANIA TALEEN G
IPC分类号： C07D495/04 , A61K31/381 , A61P25/00 , A61P25/18 , C07D333/56 , C07D495/20

39. 发明专利

ES2594156T3 Cicloalquilaminas como inhibidores de la recaptación de monoaminas 未知
公开(公告)号：ES2594156T3
公开(公告)日：2016-12-16
申请号：ES07716419
申请日：2007-01-05
申请人： SUNOVION PHARMACEUTICALS INC
发明人： SHAO LIMING , WANG FENGJIANG , MALCOLM SCOTT CHRISTOPHER , HEWITT MICHAEL CHARLES , BUSH LARRY R , MA JIANGUO , VARNEY MARK A , CAMPBELL UNA , ENGEL SHARON RAE , HARDY LARRY WENDELL , KOCH PATRICK , CAMPBELL JOHN E
IPC分类号： A61K31/381 , A61K31/335
摘要： Un compuesto que tiene una estructura de acuerdo con la Fórmula (II):**Fórmula** en donde m es un entero de 0 a 12, que no es mayor que 10 Ar es**Fórmula** en donde Y y Z son cada uno independientemente halógeno; o Ar es**Fórmula** en donde Y1, Z1, Y2, Z2 y son miembros seleccionados independientemente del grupo que consiste de: H, halógeno, CN, CF3, OMe, OEt y OCF3; cada X es un miembro seleccionado independientemente del grupo que consiste de H, halógeno, CN, CF3, OR5, SR5, acilo, C(O)OR5, C(O)NR6R7, S(O)2R5, S(O)2NR6R7, NR6R7, NR6S(O)2R5, NR6C(O)R5, alquilo sustituido o no sustituido, heteroalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido y heterocicloalquilo sustituido o no sustituido, en donde cada R5, R6 y R7 es un miembro seleccionado independientemente del grupo que consiste de H, acilo, alquilo sustituido o no sustituido, heteroalquilo sustituido o no sustituido, arilo sustituido o no sustituido y heteroarilo sustituido o no sustituido, en donde dos de R5, R6 y R7, junto con los átomos a los que están unidos, se unen opcionalmente para formar un anillo de 3 a 7 miembros; cada R1 y R2 es un miembro seleccionado independientemente del grupo que consiste de H y (C1-C4) alquilo sustituido o no sustituido; R3 y R4 son miembros seleccionados independientemente del grupo que consiste de H, alquilo sustituido o no sustituido y heteroalquilo sustituido o no sustituido; con la condición de que el compuesto no es:**Fórmula** y cualquier sal, enantiómero, diastereómero, mezcla racémica, mezcla enantioméricamente enriquecida, y forma enantioméricamente pura farmacéuticamente aceptable de la misma; en donde los sustituyentes para los radicales alquilo, heteroalquilo y heterocicloalquilo se seleccionan del grupo que consiste de: alquilo no sustituido, heteroalquilo no sustituido, arilo no sustituido, heteroarilo no sustituido, heterocicloalquilo no sustituido-OR', >=O, >=NR' >=N-OR', -NR'R",-SR', -halógeno, -SiR'R"R"', -OC(O)R', -C(O)R', - CO2R', -CONR'R", -OC(O)NR'R",-NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')>=NR"", - NRC(NR'R")>=NR"', -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -CN y -NO2 en un número que varía de cero a (2m'+1), donde m' es el número total de átomos de carbono en tal radical; R', R", R'" y R"" se refieren cada uno independientemente a hidrógeno, heteroalquilo no sustituido, arilo no sustituido, alquilo no sustituido, alcoxi o grupos tioalcoxi, o grupos arilalquilo; y en donde los sustituyentes para los grupos arilo y heteroarilo se seleccionan del grupo que consiste de: alquilo no sustituido, heteroalquilo no sustituido, arilo no sustituido, heteroarilo no sustituido, heterocicloalquilo no sustituido, -- OR', >=O, >=NR' >=N-OR', -NR'R", -SR', -halógeno,-SiR'R"R"', -OC(O)R', -C(O)R', -CO2R', -CONR'R", - OC(O)NR'R", - NR"C(O)R', -NR'-C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')>=NR"", -NR-C(NR'R")>=NR"', - S(O)R',-S(O)2R', -S(O)2NR'R", -NRSO2R', -CN, -NO2, -R', -N3, -CH(Ph)2, fluoro(C1-C4)alcoxi, y fluoro(C1- C4)alquilo, en un número que va de cero al número total de valencias abiertas en el sistema de anillo aromático; y donde R', R", R'" y R"" se seleccionan cada uno independientemente de hidrógeno, alquilo no sustituido, heteroalquilo no sustituido, arilo no sustituido y heteroarilo no sustituido.

40. 发明专利

NZ626068A Multicyclic compounds and methods of use thereof 未知
公开(公告)号：NZ626068A
公开(公告)日：2016-06-24
申请号：NZ62606810
申请日：2010-12-03
申请人： SUNOVION PHARMACEUTICALS INC , PGI DRUG DISCOVERY LLC
发明人： CAMPBELL JOHN EMMERSON , CAMPBELL UNA , HANANIA TALEEN G , HEWITT MICHAEL CHARLES , SHAO LIMING
IPC分类号： C07D495/04 , A61K31/35 , A61K31/381 , A61P25/00 , A61P25/18
摘要： Disclosed are thieno[3,2-c]pyran derivatives as represented by the general formula (IIa) or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R1 and R2 are each independently hydrogen, alkyl, or cycloalkyl, each of which is optionally substituted, or R1 and R2 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclyl or heteroaryl, wherein at least one of R1 and R2 is not hydrogen; R3 and R4 are each independently (i) hydrogen or optionally substituted alkyl; or (ii) R3 and R4 together with the carbon atom to which they are attached form an optionally substituted cycloalkyl or heterocyclyl ring; or (iii) R3 and R1 together with the atoms to which they are attached form an optionally substituted heterocyclyl, and R4 is hydrogen; or (iv) R3 and R4 are combined together to form a double bond and together with R1 and/or R2 and the atoms to which they are attached form an optionally substituted heteroaryl; R5 is hydrogen or optionally substituted alkyl; R6 and R7 are each independently (i) hydrogen, halo, alkyl, alkoxyl, aminoalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, or aralkyl, each of which is optionally substituted; or (ii) –(CH2)p–R11, wherein R11 is heteroaryl; m is 0; n is 1; and each occurrence of p is 0; wherein the substituents and terms such as hydrogen, alkyl, alkenyl, cycloalkyl, alkoxyl, aminoalkyl etc. are as defined herein. Representative compounds include N,N-dimethyl-6,7-dihydro-4H-thieno[3,2-c]pyran-4-methanamine, N-methyl-6,7-dihydro-4H-thieno[3,2-c]pyran-4-methanamine, N-methyl-2-(pyridin-4-yl)-6,7-dihydro-4H-thieno[3,2-c]pyran-4-methanamine, 2-methyl-4-(pyrrolidin-1-ylmethyl)-6,7-dihydro-4H-thieno[3,2-c]pyran, 4-(pyrrolidin-2-yl)-6,7-dihydro-4H-thieno[3,2-c]pyran and N-methyl-1-(6,7-dihydro-4H-thieno[3,2-c]pyran-4-yl)cyclopropylamine. Also disclosed is a pharmaceutical composition comprising a compound as defined above, or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient or carrier for treating, preventing, or managing a neurological disorder in a subject, particularly where the disorder is psychosis, schizophrenia or a delusional disorder.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式